TARA — Protara Therapeutics Share Price
0.000.00%
Last trade - 00:00- $138.11m
- -$32.18m
- 41
- 38
- 58
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.83 | ||
| Price to Tang. Book | 0.83 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.83% | ||
| Return on Equity | -37.88% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
Directors
- Luke Beshar NEC (63)
- Jesse Shefferman PRE (49)
- Blaine Davis CFO (47)
- Jacqueline Zummo COO (40)
- Justine O'Malley VPR
- Jathin Bandari OTH
- Jane Huang DRC
- Barry Flannelly IND (63)
- Roger Garceau IND (67)
- Richard Levy IND (63)
- Gregory Sargen IND (55)
- Cynthia Smith IND (52)
- Michael Solomon IND (51)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 24th, 2006
- Public Since
- October 22nd, 2014
- No. of Shareholders
- 26
- No. of Employees
- 28
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 38,579,021
- Address
- 345 Park Avenue South, 3Rd Floor, NEW YORK, 10010
- Web
- https://protaratx.com/
- Phone
- +1 6468440337
- Contact
- Justine O'Malley
- Auditors
- Ernst & Young LLP
Upcoming Events for TARA
Protara Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Protara Therapeutics Inc Earnings Release
Similar to TARA
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Protara Therapeutics share price?
As of Today at 22:46 UTC, shares in Protara Therapeutics are trading at $3.58. This share price information is delayed by 15 minutes.
How has the Protara Therapeutics share price performed this year?
Shares in Protara Therapeutics last closed at $3.58 and the price had moved by +23.88% over the past 365 days. In terms of relative price strength the Protara Therapeutics share price has outperformed the S&P500 Index by +11.7% over the past year.
What are the analyst and broker recommendations for Protara Therapeutics?
The overall consensus recommendation for Protara Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Protara Therapeutics dividend yield?
Protara Therapeutics does not currently pay a dividend.
Does Protara Therapeutics pay a dividend?
Protara Therapeutics does not currently pay a dividend.
When does Protara Therapeutics next pay dividends?
Protara Therapeutics does not currently pay a dividend.
How do I buy Protara Therapeutics shares?
To buy shares in Protara Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Protara Therapeutics?
As of the previous close price of $3.58, shares in Protara Therapeutics had a market capitalisation of $138.11m.
Where are Protara Therapeutics shares listed?
Here are the trading details for Protara Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: TARA
What kind of share is Protara Therapeutics?
Based on an overall assessment of its quality, value and momentum Protara Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Protara Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Protara Therapeutics is $22.40. That is 525.7% above the last closing price of $3.58.
Analysts covering Protara Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.69 for the next financial year.
Find out moreWhat is the trend in the Protara Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Protara Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +45.6%.
As of the last closing price of $3.58, shares in Protara Therapeutics were trading +6.6% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Protara Therapeutics PE Ratio?
The Protara Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Protara Therapeutics?
Protara Therapeutics' management team is headed by:
- Luke Beshar - NEC
- Jesse Shefferman - PRE
- Blaine Davis - CFO
- Jacqueline Zummo - COO
- Justine O'Malley - VPR
- Jathin Bandari - OTH
- Jane Huang - DRC
- Barry Flannelly - IND
- Roger Garceau - IND
- Richard Levy - IND
- Gregory Sargen - IND
- Cynthia Smith - IND
- Michael Solomon - IND